ValuEngine cut shares of TESARO Inc (NASDAQ:TSRO) from a hold rating to a sell rating in a research report sent to investors on Monday, July 17th.
Several other brokerages have also recently issued reports on TSRO. Janney Montgomery Scott set a $139.00 price target on shares of TESARO and gave the company a hold rating in a research report on Saturday, June 10th. Zacks Investment Research upgraded shares of TESARO from a sell rating to a hold rating in a report on Friday, March 31st. Cowen and Company set a $145.00 price objective on shares of TESARO and gave the company a hold rating in a research note on Saturday, June 10th. Robert W. Baird reissued a neutral rating on shares of TESARO in a research report on Tuesday, June 6th. Finally, FBR & Co decreased their price objective on shares of TESARO from $202.00 to $200.00 and set a mkt perform rating for the company in a report on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of $176.35.
TESARO (TSRO) traded up 0.87% during midday trading on Monday, hitting $111.85. 800,674 shares of the company traded hands. The company’s market capitalization is $6.06 billion. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94. The stock’s 50-day moving average price is $130.46 and its 200 day moving average price is $149.15.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 516.08% and a negative return on equity of 133.59%. The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the firm earned ($1.28) EPS. The business’s revenue for the quarter was down 17.6% on a year-over-year basis. On average, equities analysts forecast that TESARO will post ($8.45) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “TESARO Inc (NASDAQ:TSRO) Downgraded by ValuEngine” was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.baseball-news-blog.com/2017/08/14/tesaro-inc-nasdaqtsro-rating-lowered-to-sell-at-valuengine-updated-updated-updated.html.
In related news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 40.50% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in TSRO. Botty Investors LLC bought a new position in TESARO during the second quarter worth $140,000. Nordea Investment Management AB acquired a new stake in shares of TESARO during the second quarter valued at about $167,000. Meeder Asset Management Inc. bought a new stake in TESARO during the first quarter valued at $177,000. Oppenheimer Asset Management Inc. boosted its stake in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC bought a new stake in TESARO during the second quarter valued at $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.